Methods of treating tyrosine kinase inhibitor-induced diarrhea
AssigneeThe Regents of the University of California
InventorAlan S. VERKMAN
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to methods of treating tyrosine kinase inhibitor-induced diarrhea by administering a potassium channel inhibitor, or a CFTR chloride channel inhibitor, or a combination thereof.
Claims37
A method of:
- treating a subject with tyrosine kinase inhibitor-induced diarrhea;
- reducing intestinal fluid secretion resulting from tyrosine kinase inhibitor-induced activation of potassium channels or tyrosine kinase inhibitor-induced activation of CFTR chloride channels in the intestinal epithelium in a subject in need thereof;
- reducing tyrosine kinase inhibitor-induced potassium channel current or tyrosine kinase inhibitor-induced CFTR chloride channel current in the intestinal epithelium of a subject in need thereof;
- or
- treating diarrhea in a subject being administered a tyrosine kinase inhibitor wherein the method comprises determining whether the diarrhea is tyrosine kinase inhibitor-induced diarrhea;
- said method comprising administering to said subject a potassium channel inhibitor, or a CFTR chloride channel inhibitor, or a combination of a potassium channel inhibitor and CFTR chloride channel inhibitor.
9-22. (canceled)
A method of treating cancer in a subject consisting essentially of administering to the subject an amount of a tyrosine kinase inhibitor effective to treat the subject's cancer and administering to said subject a potassium channel inhibitor, or a CFTR chloride channel inhibitor, or a combination of a potassium channel inhibitor and CFTR chloride channel inhibitor.
30-36. (canceled)
A method of treating cancer in a subject, wherein the method comprises administering to the subject an amount of a tyrosine kinase inhibitor effective to treat the subject's cancer, wherein said method further comprises administering to the subject a potassium channel inhibitor, or a CFTR chloride channel inhibitor, or a combination of a potassium channel inhibitor and CFTR chloride channel inhibitor.
Dependencies are inferred from the claim text.